Cancer Immunology Reserch

Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0484. Online ahead of print. ABSTRACT The limited infiltration of CD8+ T cells in tumors hampers the effectiveness of T cell-based immunotherapy, yet the mechanisms that limit tumor infiltration by CD8+ T cells remain unclear. Through bulk RNA sequencing of human tumors, we identified a strong correlation between … Read more

Cancer Immunol Res. 2024 Nov 26. doi: 10.1158/2326-6066.CIR-23-0514. Online ahead of print. ABSTRACT Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators of immunity to melanoma, we performed a whole-genome CRISPR screen in melanoma and identified Setdb1 as well as all components … Read more

Cancer Immunol Res. 2024 Nov 25. doi: 10.1158/2326-6066.CIR-24-0245. Online ahead of print. ABSTRACT Pleural mesothelioma (PM) is a fatal disease with limited treatment options. Recently, PM management has improved with the development of immune checkpoint inhibitors (ICIs). In first-line therapy, dual PD-1 and CTLA-4 blockade enhances tumor control and patient survival compared with chemotherapy. Unfortunately, … Read more

Cancer Immunol Res. 2024 Nov 21. doi: 10.1158/2326-6066.CIR-24-0124. Online ahead of print. ABSTRACT Approximately 70% of patients receiving immune checkpoint blockade therapies develop treatment resistance. Thus, there is a need for the identification of additional immunotherapeutic targets. CD49a is a membrane protein expressed on NK cells and T cells. In this study, we found that … Read more

Cancer Immunol Res. 2024 Nov 15. doi: 10.1158/2326-6066.CIR-24-0273. Online ahead of print. ABSTRACT Natural killer (NK) cell tumor infiltration is associated with good prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC). NK cells recognize and kill targets by a process called natural cytotoxicity. We hypothesized that promoting an antigen-specific synapse with co-activation may enhance … Read more

Cancer Immunol Res. 2024 Nov 14:OF1. doi: 10.1158/2326-6066.CIR-24-1029. Online ahead of print. NO ABSTRACT PMID:39540853 | DOI:10.1158/2326-6066.CIR-24-1029

Cancer Immunol Res. 2024 Nov 12. doi: 10.1158/2326-6066.CIR-24-0084. Online ahead of print. ABSTRACT Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer with a low rate of response to immunotherapy such as immune checkpoint blockade (ICB) therapy. Here, we report that nucleus accumbens-associated protein 1 (NAC1), a putative driver of EOC, has … Read more

Cancer Immunol Res. 2024 Nov 11. doi: 10.1158/2326-6066.CIR-24-0561. Online ahead of print. ABSTRACT Anti-PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma (EGA), but long-term survival remains limited. Herein, we report extended follow-up data from the INTEGA trial (NCT03409848), which investigated the efficacy of the anti-PD-1 nivolumab, trastuzumab, … Read more

Cancer Immunol Res. 2024 Nov 8. doi: 10.1158/2326-6066.CIR-24-0324. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of unresectable hepatocellular carcinoma (HCC), but their impressive efficacy is seen in just a fraction of patients. One key mechanism of immunotherapy resistance is the paucity of dendritic cells (DCs) in liver malignancies. Here, … Read more

Cancer Immunol Res. 2024 Nov 1. doi: 10.1158/2326-6066.CIR-24-0320. Online ahead of print. ABSTRACT Major histocpmpatibilty complex class I (MHC I) antigen presentation allows CD8+ T cells to detect and eliminate cancerous or virally infected cells. The MHC I pathway is not essential for cell growth and viability and consequently cancers and viruses can evade control … Read more